OVERVIEW

Treating Cancer by Blocking Cell Signals

Alex A. Adjei and Manuel Hidalgo

JCO Aug 10 2005: 5279–5280. [Full Text] [PDF]

ORIGINAL REPORTS
Molecular Oncology
	Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
	Patricia M. LoRusso, Alex A. Adjei, Mary Varterasian, Shirish Gadgeel, Joel Reid, David Y. Mitchell, Lorelei Hanson, Pamela DeLuca, Laura Bruzek, Jill Piens, Peggy Asbury, Keri Van Becelaere, Roman Herrera, Judith Sebolt-Leopold, and Mark B. Meyer
	JCO Aug 10 2005: 5281–5293. First published on Jul 11 2005; 10.1200/JCO.2005.14.415. [Abstract] [Full Text] [PDF]
	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
	Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, Jeffrey I. Kreisberg, Karla Ballman, J. Boni, Josep M. Peralba, Robert B. Jenkins, Shaker R. Dakhil, Roscoe F. Morton, Kurt A. Jaeckle, Bernd W. Scheithauer, Janet Dancey, Manuel Hidalgo, and Daniel J. Walsh
	JCO Aug 10 2005: 5294–5304. First published on Jul 5 2005; 10.1200/JCO.2005.23.622. [Abstract] [Full Text] [PDF]
	Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
	Howard A. Burris, III, Herbert I. Hurwitz, E. Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O'Neil, Paul K. Marcom, Matthew J. Ellis, Beth Overmoyer, Suzanne F. Jones, Jennifer L. Harris, Deborah A. Smith, Kevin M. Koch, Andrew Stead, Steve Mangum, and Neil L. Spector
	JCO Aug 10 2005: 5305–5313. First published on Jun 13 2005; 10.1200/JCO.2005.16.584. [Abstract] [Full Text] [PDF]
	Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
	Stephen Chan, Max E. Scheulen, Stephen Johnston, Klaus Mross, Fatima Cardoso, Christian Dittrich, Wolfgang Eiermann, Dagmar Hess, Rudolph Morant, Vladimir Semiglazov, Markus Borner, Marc Salzberg, Valerijus Ostapenko, Hans-Joachim Illiger, Dirk Behringer, Nathalie Bardy-Bouxin, Joseph Boni, Steven Kong, Maria Cincotta, and Laurence Moore
	JCO Aug 10 2005: 5314–5322. First published on Jun 13 2005; 10.1200/JCO.2005.66.130. [Abstract] [Full Text] [PDF]
	Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
	José Baselga, Joan Albanell, Amparo Ruiz, Ana Lluch, Pere Gascón, Vicente Guillém, Sonia González, Silvia Sauleda, Irene Marimón, Josep M. Tabernero, Maria T. Koehler, and Federico Rojo
	JCO Aug 10 2005: 5323–5333. First published on Jun 6 2005; 10.1200/JCO.2005.08.326. [Abstract] [Full Text] [PDF]
	Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma
	Angelo Vacca, Claudio Scavelli, Vittorio Montefusco, Giulia Di Pietro, Antonino Neri, Michela Mattioli, Silvio Bicciato, Beatrice Nico, Domenico Ribatti, Franco Dammacco, and Paolo Corradini
	JCO Aug 10 2005: 5334–5346. First published on Jun 6 2005; 10.1200/JCO.2005.03.723. [Abstract] [Full Text] [PDF]
	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
	Thomas E. Witzig, Susan M. Geyer, Irene Ghobrial, David J. Inwards, Rafael Fonseca, Paul Kurtin, Stephen M. Ansell, Ronnie Luyun, Patrick J. Flynn, Roscoe F. Morton, Shaker R. Dakhil, Howard Gross, and Scott H. Kaufmann
	JCO Aug 10 2005: 5347–5356. First published on Jun 27 2005; 10.1200/JCO.2005.13.466. [Abstract] [Full Text] [PDF]
	PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
	Christopher L. Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina Harrell, Sharon Shiraga, Troy Bainbridge, Jason Morich, and Michael C. Heinrich
	JCO Aug 10 2005: 5357–5364. First published on May 31 2005; 10.1200/JCO.2005.14.068. [Abstract] [Full Text] [PDF]
	Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB4 Receptor Antagonist, in Patients With Advanced Solid Tumors
	Gary K. Schwartz, Aaron Weitzman, Eileen O'Reilly, Les Brail, Dinesh P. de Alwis, Ann Cleverly, Barbara Barile-Thiem, Vincent Vinciguerra, and Daniel R. Budman
	JCO Aug 10 2005: 5365–5373. First published on Jun 6 2005; 10.1200/JCO.2005.02.766. [Abstract] [Full Text] [PDF]

REVIEW ARTICLES
	Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
	Steven J. Cohen, Roger B. Cohen, and Neal J. Meropol
	JCO Aug 10 2005: 5374–5385. First published on Jul 5 2005; 10.1200/JCO.2005.02.194. [Abstract] [Full Text] [PDF]
	Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
	Alex A. Adjei and Manuel Hidalgo
	JCO Aug 10 2005: 5386–5403. First published on Jun 27 2005; 10.1200/JCO.2005.23.648. [Abstract] [Full Text] [PDF]

GLOSSARY

Glossary

JCO Aug 10 2005: 5406–5415. [PDF]

SPECIAL DEPARTMENTS

Correspondence

Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

Roderich E. Schwarz and David D. Smith

JCO Aug 10 2005: 5404–5405. [Full Text] [PDF]

In Reply:

H.H. Hartgrink, H. Putter, and C.J.H. van de Velde

JCO Aug 10 2005: 5405. [Full Text] [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.